Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Reiter

Showing results (1-10 of 211) with videos related to

Pageof 22
Sort By:
Current Hematologic Malignancy Reports|February 20, 2016
How We Identify and Manage Patients with Inadequately Controlled Polycythemia VeraAndreas Reiter, Claire Harrison
Blood|December 29, 2016
Myeloid neoplasms with eosinophiliaAndreas Reiter, Jason Gotlib
International Orthopaedics|October 21, 2003
The periprosthetic bone remodelling process--signs of vital bone reactionArnim Braun, Jan Papp, Andreas Reiter
Acta Haematologica|June 5, 2004
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemiaAndreas Reiter, Eva Lengfelder, David Grimwade
Acta Haematologica|June 21, 2008
Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disordersNicholas C P Cross, Andreas Reiter
Frontiers in Immunology|June 29, 2026
Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseasesJohannes Lübke, Andreas Reiter, Juliana Schwaab
Blood|July 25, 2022
Avapritinib for advanced systemic mastocytosisJason Gotlib, Andreas Reiter, Daniel J DeAngelo
Blood|February 28, 2020
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosisAndreas Reiter, Tracy I George, Jason Gotlib
Current Drug Targets|February 20, 2007
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disordersAndreas Reiter, Christoph Walz, Nicholas C P Cross
Current Hematologic Malignancy Reports|July 22, 2024
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicalsJohannes Lübke, Georgia Metzgeroth, Andreas Reiter, et al.
Pageof 22

Showing results (1-10 of 211) with videos related to

Sort By:
Pageof 22
Current Hematologic Malignancy Reports|February 20, 2016
How We Identify and Manage Patients with Inadequately Controlled Polycythemia VeraAndreas Reiter, Claire Harrison
Blood|December 29, 2016
Myeloid neoplasms with eosinophiliaAndreas Reiter, Jason Gotlib
International Orthopaedics|October 21, 2003
The periprosthetic bone remodelling process--signs of vital bone reactionArnim Braun, Jan Papp, Andreas Reiter
Acta Haematologica|June 5, 2004
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemiaAndreas Reiter, Eva Lengfelder, David Grimwade
Acta Haematologica|June 21, 2008
Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disordersNicholas C P Cross, Andreas Reiter
Frontiers in Immunology|June 29, 2026
Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseasesJohannes Lübke, Andreas Reiter, Juliana Schwaab
Blood|July 25, 2022
Avapritinib for advanced systemic mastocytosisJason Gotlib, Andreas Reiter, Daniel J DeAngelo
Blood|February 28, 2020
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosisAndreas Reiter, Tracy I George, Jason Gotlib
Current Drug Targets|February 20, 2007
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disordersAndreas Reiter, Christoph Walz, Nicholas C P Cross
Current Hematologic Malignancy Reports|July 22, 2024
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicalsJohannes Lübke, Georgia Metzgeroth, Andreas Reiter, et al.
Pageof 22